AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04109118 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: BZD discontinuation protocol
Description: All participants will undergo BZD discontinuation. Once the starting BZD dose is determined by prescription monitoring and/or self-report, we will maintain participants on this dose until the start of the BZD taper. Participants will see a study physician weekly to receive their BZD medication for the week until the taper is completed. BZD discontinuation in this study will consist of a gradual BZD taper in dose over 9 weeks. The taper will be flexible in that the study physician will utilize clinical judgement to lengthen the taper if necessary, depending on the severity of the participant's withdrawal symptoms. Anchor points will be set (33% reduction in dose after 2 weeks, 50% mid-treatment, 100% by week 8) to emphasize the time-limited nature of the taper.
Study NCT05183763 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STAR-MAP health coaching
Description: Interactive health coaching delivered in 11 sessions over one year; focusing on using adaptive change tactics to improve medication-taking behavior
Study NCT05556356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: pre-operative acetaminophen (1000mg)
Study NCT05556356 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Multivitamin
Description: pre-operative Multivitamin
Study NCT05183763 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Medication reminder tools
Description: Medication-taking reminder app and pillbox
Study NCT05183763 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication reminder tools
Description: Medication-taking reminder app and pillbox
Study NCT00535457 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preoperative Magic Tricks
Description: Watching magic; Study patients will watch the anesthesiologist performing tricks (magic) before anesthesia induction.
Study NCT06637410 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High intensity laser therapy
Description: HILT was performed by a single physiotherapist experienced in using a laser device. During HILT application, the patients were seated comfortably on chairs and their shoulders were in neutral position. The wavelength of the laser light used was 1064 nanometers. In the HILT group, the device was used on the rotator cuff muscles in two stages: phase I and phase II. Pulse method was used in phase I for analgesic effect. A standard frequency of 25 Hz is applied. During the first four therapy sessions, it was aimed to provide an analgesic effect by using 8 W power and 12 J/cm dose. The rays were applied to the rotator cuff muscles area in a circle from outside to inside for 2.5 minutes, for a total energy of 300 J, on an area of 25 cm2. For the biostimulation effect, the continuous wave method was used in phase II. n the next five sessions, biostimulation effect was applied using 7W power. A dose of 100 J/cm was applied longitudinally to the rotator cuff muscles.
Study NCT06637410 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound therapy
Description: US therapy was performed by a single physiotherapist experienced in using US device. Calibration and control of the device are performed regularly. During US therapy, the patients were seated comfortably on chairs and their shoulders were in neutral position. The standard US dose was 1.2 W/cm2. The duration of ultrasound was 8 minutes. Using slow circular movements, the physiotherapist applied the transducer head of US device over the shoulder joint on an area of 25 cm2. US device was used in pulsed mode at a frequency of 1 MHz. The therapeutic ultrasound pulse cycle was 50%.
Study NCT06637410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Exercise
Description: ROM exercises and Codman exercises, in a level not to increase the severity of the pain of the patient, were given and stretching and strengthening exercises were taught to the patients. They performed these exercises daily in two sets with five repeats in each set underCalibration and control of the device are performed regularly.
Study NCT06402630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STS01
Description: Participants are block randomised to be treated with 0.25%, 0.5%, 1.0%, 2% STS-01 or a matching placebo control topically once daily for 6 months with a 2-month follow up.
Study NCT06637410 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Exercise
Description: ROM exercises and Codman exercises, in a level not to increase the severity of the pain of the patient, were given and stretching and strengthening exercises were taught to the patients. They performed these exercises daily in two sets with five repeats in each set underCalibration and control of the device are performed regularly.
Study NCT03553615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin Pill
Description: oral anti-parasitic agent taken as a weekly dose for four weeks
Study NCT06642493 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma
Description: Intervention Type: Biological~* Intervention Name: Fresh Frozen Plasma (FFP)~* Detailed Description:~* Dosage:Fresh frozen plasma (FFP) will be administered at a dose of 10-15 mL/kg body weight.~* Administration: The FFP will be transfused intravenously under controlled clinical conditions.~* Purpose: The transfusion aims to correct coagulopathy and normalize activated partial thromboplastin time (aPTT) in non-bleeding thrombocytopenic dengue patients.~* Monitoring: Patients will be closely monitored for any adverse reactions or complications during and after the transfusion process. Coagulation parameters, including aPTT, will be measured at baseline, 24 hours, and 48 hours post-transfusion.
Study NCT06642493 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Fresh frozen plasma
Description: Intervention Type: Biological~* Intervention Name: Fresh Frozen Plasma (FFP)~* Detailed Description:~* Dosage:Fresh frozen plasma (FFP) will be administered at a dose of 10-15 mL/kg body weight.~* Administration: The FFP will be transfused intravenously under controlled clinical conditions.~* Purpose: The transfusion aims to correct coagulopathy and normalize activated partial thromboplastin time (aPTT) in non-bleeding thrombocytopenic dengue patients.~* Monitoring: Patients will be closely monitored for any adverse reactions or complications during and after the transfusion process. Coagulation parameters, including aPTT, will be measured at baseline, 24 hours, and 48 hours post-transfusion.
Study NCT06015516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minoxidil Tablets
Description: Since oral minoxidil is a new formulation and, according to the recommendations of the Regulatory Authorities, it is considered appropriate to carry out a multiple dose study to evaluate and to compare the bioavailability between both formulations (oral versus topical solution), measuring the plasma concentrations of minoxidil.~Achievement of steady-state is assessed by comparing at least three pre-dose concentrations for each formulation, as half-life of minoxidil is around 4 hours, we will administered 5 doses in each period.
Study NCT06015516 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minoxidil topical solution 20 mg/ml
Description: Since oral minoxidil is a new formulation and, according to the recommendations of the Regulatory Authorities, it is considered appropriate to carry out a multiple dose study to evaluate and to compare the bioavailability between both formulations (oral versus topical solution), measuring the plasma concentrations of minoxidil.~Achievement of steady-state is assessed by comparing at least three pre-dose concentrations for each formulation, as half-life of minoxidil is around 4 hours, we will administered 5 doses in each period.
Study NCT06642194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education on sunnah of sleeping
Description: The interventions had three session which conducted between 40-60 minutes per session. The session include: 1) introducing the research objectives, definition and benefits on sunnah of sleeping; 2) steps in sunnah of sleeping (early bedtime and early wake up time; perform ablution (wudoo) before going to bed and supplicate; dusting and cleaning the bed before sleeping; sleep position; turning off light before sleep; cover mouth when yawning and reciting some verses such as Ayat Kursi, Al-Ikhlas, Al-Falq and An-Nas); 3) providing mp3 and prayers beads to facilitate Qur'an recitation and zikr. These surat was chosen because the portion of surat concentrate on the absolute divinity of Allah and Allah's blessings to His creatures. The surat brings every Muslim the closeness to Allah, the calmness of the soul, and the cure for many physical and psychological diseases. The steps in sunnah of sleeping can be performed approximately about 10-15 minutes about 30 minutes prior to sleep.
Study NCT06564038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD0486
Description: AZD0486 will be administered as either SC injection (substudies 1 and 2) or IV infusion (substudy 3).
Study NCT06564038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Acalabrutinib tablet will be administered orally twice daily.
Study NCT06402630 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants are block randomised to be treated with 0.25%, 0.5%, 1.0%, 2% STS-01 or a matching placebo control topically once daily for 6 months with a 2-month follow up.
Study NCT05407818 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-63733657
Description: JNJ-63733657 will be administered as an IV infusion.
Study NCT05049668 — intervention group
Intervention type: DRUG
Intervention: ATGAM plus CsA with or without Eltrombopag
Description: Standard treatment with or without Eltrombopag
Study NCT06564038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone will be administered either oral or IV infusion as per standard of care.
Study NCT05117450 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Decrease per-dialytic heparin therapy
Description: Decrease per-dialytic heparin therapy with the HYDROLINK membrane (dialyzer NV-21U, surface 2.1m², Toray industry, Tokyo, Japan) and with the HeprAN membrane (dialyzer Evodial 2.2, surface 2.15 m2, Hospal SAS, Meyzieu, France)
Study NCT05096117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8062
Description: ASP8062 is a novel compound with positive allosteric modulator (PAM) activity on the γ-aminobutyric acid type B (GABAB) receptor, 25 mg, 1 x per day for 6 weeks
Study NCT05096117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 x per day for 6 weeks
Study NCT05376488 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: One meal
Description: One meal given to assess impact on ammonia levels serially
Study NCT05376488 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: One meal
Description: One meal given to assess impact on ammonia levels serially
Study NCT06000969 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lung Recruitment Conventional
Description: the recruitment maneuver will be performed by manual inflation with a pressure of 30 cmH2O for 30 seconds.
Study NCT06000969 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lung Recruitment Ultrasound
Description: the recruitment maneuver will be performed under the direct real-time guidance of ultrasound if atelectasis (defined as LUS of ≥ 2 for any of the 12 regions) is present. This will be done by manual inflation with a pressure of 10 cmH2O for 10 seconds, increased 10 cmH2O every 10 seconds until no collapsed areas are visible on the ultrasound, the maximum airway pressure will be limited to 40 cmH2O. This could be repeated if needed.
Study NCT04222270 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Champion Caregiver peer mentoring support to caregivers on child care and medication adherence to enhance achievement of viral suppression
Description: Caregiver to caregiver peer support intervention through group/one-on-one education and counselling
Study NCT06033300 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Description: blood sample
Study NCT05202080 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opioid Counseling and Pain Coping Skills Video
Description: The intervention will be in the form of a video of a PowerPoint presentation with instructions and exercises designed to coach patients about catastrophizing, coping skills, mindfulness and behavioral modification techniques, in addition to providing education regarding postoperative analgesia and opioid use.
Study NCT05797545 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Breast MRI for Breast Cancer Detection
Description: Comparison of diagnostic results of abbreviated breast MRI and full protocol MRI for secondary breast cancer surveillance
Study NCT06564038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab will be administered as IV infusion as per standard of care.
Study NCT06564038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide will be administered as IV infusion as per standard of care.
Study NCT06564038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine will be administered as IV infusion as per standard of care.
Study NCT05917717 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuroprotective 'bundle of care'
Description: This includes the 3 devices:~* Head up cardiopulmonary resuscitation (HUP-CPR)~* Active compression decompression CPR~* Impedance threshold device (ITD)
Study NCT06564038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin will be administered as IV infusion as per standard of care.
Study NCT05843604 — intervention group
Intervention type: OTHER
Intervention: Functional MRI
Description: Three cognitive tests will be performed in the MRI, namely a stroop task, an N-back task and a switching task
Study NCT05630755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOR/ISL
Description: DOR/ISL 100 mg/0.25 mg oral tablets once daily
Study NCT05630755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIC/FTC/TAF
Description: BIC/FTC/TAF 50 mg/200 mg/25 mg oral tablets once daily
Study NCT05391126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Usual dosing per package insert.
Study NCT06555965 — intervention group
Intervention type: OTHER
Intervention: Non-interventional study
Description: There is no planned intervention in this study
Study NCT05231122 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-CD40 Agonist Monoclonal Antibody CDX-1140
Description: Given IV
Study NCT05630755 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BIC/FTC/TAF
Description: 0 mg oral tablets once daily
Study NCT05630755 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to DOR/ISL
Description: 0 mg oral tablets once daily
Study NCT06288009 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Running locking suture
Description: In running locking sutures, the first anchoring knot is made at one end of the wound, and a loop of suture is left from the beginning of the throw. The needle is then passed through the loop of suture, locking the suture in place. This is repeated until reaching the end of the wound, where the suture material is then tied to the loop using an instrument tie for the final throw.
Study NCT06288009 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard running suture
Description: In standard running sutures, the first anchoring knot is made at one end of the wound, and all of the suture material is pulled through after completing the throw. This is repeated until reaching the end of the wound, where the suture material is then tied.
Study NCT05775354 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Early diagnosis strategy
Description: RED-CVD early diagnosis questionnaire, physical examination, laboratory testing, electrocardiography, echocardiography
Study NCT05015530 — intervention group
Intervention type: DEVICE
Intervention: Healsea® Chronic, hypertonic seawater-based nasal spray supplemented with natural Symbiofilm® extract
Description: Healsea® Chronic nasal spray will be administered twice daily (1 puff, 1-2 sec) in each nostril during 30 days
Study NCT06046833 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeStyle Libre 3 continuous glucose monitoring sensor
Description: The Freestyle Libre 3 sensor is a small real-time continuous glucose monitor device that measures glucose levels every minute
Study NCT06046833 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FreeStyle Libre 3 continuous glucose monitoring sensor
Description: The Freestyle Libre 3 sensor is a small real-time continuous glucose monitor device that measures glucose levels every minute
Study NCT06046833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional drink
Description: Balanced nutritional drink (Boost plus 8 ounces/237 mL)
Study NCT06046833 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional drink
Description: Balanced nutritional drink (Boost plus 8 ounces/237 mL)
Study NCT05901311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3537982
Description: Administered orally.
Study NCT05901311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [¹⁴C]-LY3537982
Description: Administered orally.
Study NCT05901311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [¹⁴C]-LY3537982
Description: Administered IV.
Study NCT04779697 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLP-1 analogue - semaglutide
Description: GLP-1 analogue - semaglutide - administered once weekly for a total of 12 weeks
Study NCT04779697 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - administered once weekly for a total of 12 weeks
Study NCT06586320 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: 150% of their routine home dopaminergic medications dose right in the clinic
Description: IPD subjects will be informed head of time not to take their dopaminergic medications and other Parkinson's non-dopaminergic medications such as anticholinergics, NMDA inhibitors, and adenosine blockers for at least 12 hours prior to their initial procedure. Immediately, after conducting both hand movement and eye movement tests, the patient will take 150% of their routine home dopaminergic medications dose right in the clinic. They will also take their non-dopaminergic medications doses similar to home dose with no change. This will be under the supervision of their treating movement disorders specialist and study PI.
Study NCT06586320 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Evaluation of mathematical models
Description: Evaluation of performance of mathematical models developed to quantify and classify symptoms and disease state using sensor data from smart phone and eye tracking cameras
Study NCT06565039 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supira System
Description: The Supira System is a minimally invasive, miniaturized percutaneous ventricular assist (pVAD) system that is intended to provide temporary (≤4 hours) hemodynamic support to patients undergoing a high-risk percutaneous coronary intervention (HRPCI). The Catheter is inserted percutaneously via the femoral artery, across the aortic valve, and into the left ventricle under fluoroscopic guidance, with a portion remaining in the ascending aorta. The left ventricle is unloaded by pumping blood from the ventricle into the ascending aorta and systemic circulation.
Study NCT05384483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Cariprazine 1.5 to 3 mg per day
Study NCT05384483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT05231122 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Given IV
Study NCT05231122 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT05231122 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Given IV
Study NCT05231122 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT05222945 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Biopsies and bloood samplings
Description: blood samples, rectal biopsies, nodes biopsies, cutaneous fat tissues biopsies, semen sample
Study NCT06582732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost Intracameral Implant exchanged at Month 12
Description: intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 12
Study NCT06582732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost Intracameral Implant exchanged at Month 3
Description: intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 3
Study NCT06582732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost Intracameral Implant exchanged at Month 6
Description: intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 6
Study NCT05231122 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT06582732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Travoprost Intracameral Implant exchanged at Month 24
Description: intracameral implant containing travoprost 75 mcg implanted on Day 1 and exchanged at Month 24